Article
An additional defective allele, CYP2C19*5, contributes to the S-mephenytoin poor metabolizer phenotype in Caucasians.
Pharmacogenetics - 1 Apr 1998
Ibeanu G C, Blaisdell J, Ghanayem B I, Beyeler C, Benhamou S, Bouchardy C, Wilkinson G R, Dayer P, Daly A K, Goldstein J A
Abstract excerpt
The metabolism of the anticonvulsant drug mephenytoin exhibits a genetic polymorphism in humans. This polymorphism exhibits marked racial heterogeneity, with the poor metabolizer PM phenotype representing 13-23% of oriental populations, but only 2-5% of Caucasian populations. Two defective CYP2C19 alleles (CYP2C19*2 and CYP2C19*3) have been described, which account for more than 99% of Oriental poor metabolizer...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.